Should You Add Oncotelic Therapeutics Inc (OTLC) Stock to Your Portfolio Wednesday?

Wednesday, July 13, 2022 10:56 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Oncotelic Therapeutics Inc (OTLC) Stock to Your Portfolio Wednesday?

Oncotelic Therapeutics Inc (OTLC) is around the bottom of the Healthcare sector according to InvestorsObserver. OTLC received an overall rating of 85, which means that it scores higher than 85% of stocks. Additionally, Oncotelic Therapeutics Inc scored a 26 in the Healthcare sector, ranking it higher than 26% of stocks in that sector.

OTLC has an Overall Score of 85. Find out what this means to you and get the rest of the rankings on OTLC!

See Full OTLC Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 85 means the stock is more attractive than 85 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Oncotelic Therapeutics Inc Stock Today?

Oncotelic Therapeutics Inc (OTLC) stock has risen 13.45% while the S&P 500 is lower by -0.51% as of 10:29 AM on Wednesday, Jul 13. OTLC is higher by $0.02 from the previous closing price of $0.12 on volume of 265,000 shares. Over the past year the S&P 500 has fallen -13.04% while OTLC is lower by -22.22%. OTLC lost -$0.03 per share the over the last 12 months. Click Here to get the full Stock Report for Oncotelic Therapeutics Inc stock.